← Leaderboards
Howard H Bailey
University Of Wisconsin Madison
$27,057,671
Attributed
$27,305,729
Total exposure
43
Grants
32
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$83,429,886 · 44
By mechanism
P30$72,365,243 · 28
UG1$4,214,327 · 1
N01$3,250,646 · 2
R01$1,575,740 · 2
M01$817,383 · 9
U01$710,430 · 1
Top collaborators
- Nihal Ahmad2 shared
- Evie Carchman2 shared
- Megan Fitzpatrick2 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Anne E Griep$8,692,152
- George Wilding$32,976,854
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMalignant NeoplasmsCancer CenterComprehensive Cancer CenterMemberWisconsinResearch PersonnelProgramsFacultyMissionFundingUniversitiesAnticancer ResearchResource SharingAreaResourcesLeadershipScienceCollaborationsInnovationPeer ReviewCancer ControlCommunitiesInstitution
Grant awards (150)
Leadership, Planning and Evaluation$546,912
P30 · FY2025 · CA · contact PI
Developmental Funds$215,358
P30 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$546,912
P30 · FY2024 · CA · contact PI
Developmental Funds$215,358
P30 · FY2024 · CA · contact PI
UW Comprehensive Cancer Center Support$194,375
P30 · FY2024 · CA · contact PI
UW Comprehensive Cancer Center Support$5,240,484
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$546,912
P30 · FY2023 · CA · contact PI
UW Comprehensive Cancer Center Support$254,830
P30 · FY2023 · CA · contact PI
UW Comprehensive Cancer Center Support$229,000
P30 · FY2023 · CA · contact PI
Developmental Funds$215,358
P30 · FY2023 · CA · contact PI
UW Comprehensive Cancer Center Support$194,375
P30 · FY2023 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$4,720,345
P30 · FY2022 · CA · contact PI
The MW Cancer Prevention Clinical Trials Network$1,652,564
UG1 · FY2022 · CA · contact PI
Developmental Funds$771,514
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$436,240
P30 · FY2022 · CA · contact PI
Biomarkers for Detection and Prediction of Chemotherapy-Related Cognitive Impairment$382,090
P30 · FY2022 · CA · contact PI
Defining Tumor Microenvironment and Response to Immune Checkpoint Blockade in HIV-related Anogenital Squamous Cell Carcinomas (Immuno/microenvironment)$244,723
P30 · FY2022 · CA · contact PI
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)$239,001
P30 · FY2022 · CA · contact PI
Dr. Syed Nabeel Zafarâs application for the NCI Early-stage Surgeon Scientist Program (ESSP)$194,375
P30 · FY2022 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$85,793
P30 · FY2022 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$52,721
P30 · FY2022 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$17,816
P30 · FY2022 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$4,588,295
P30 · FY2021 · CA · contact PI
The MW Cancer Prevention Clinical Trials Network$1,716,394
UG1 · FY2021 · CA · contact PI
Developmental Funds$789,970
P30 · FY2021 · CA · contact PI
Leadership, Planning and Evaluation$454,697
P30 · FY2021 · CA · contact PI
Administrative Supplement to UW Carbone Comprehensive Cancer Center Support Grant for the Cancer Center Cessation Initiative (C3I) Coordinating Center$300,104
P30 · FY2021 · CA · contact PI
Creating an efficient clinical trial build system via the Clinical Trials Rapid Activation Consortium (CTRAC)$150,000
P30 · FY2021 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$124,387
P30 · FY2021 · CA · contact PI
Administrative Supplement to the Cancer Center Support Grant to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network$114,392
P30 · FY2021 · CA · contact PI
Cancer Clinical Investigator Team Leadership Award P30 Administrative Supplement for FY21$52,721
P30 · FY2021 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$43,011
P30 · FY2021 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$4,590,043
P30 · FY2020 · CA · contact PI
The MW Cancer Prevention Clinical Trials Network$845,369
UG1 · FY2020 · CA · contact PI
Developmental Funds$790,047
P30 · FY2020 · CA · contact PI
Leadership, Planning and Evaluation$454,774
P30 · FY2020 · CA · contact PI
Creating An Efficient Clinical Trial Build System via The Clinical Trials Rapid Activation Consortium (CTRAC)$300,161
P30 · FY2020 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$115,000
P30 · FY2020 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$107,093
P30 · FY2020 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$106,911
P30 · FY2020 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$4,590,130
P30 · FY2019 · CA · contact PI
Developmental Funds$790,050
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$499,999
P30 · FY2019 · CA · contact PI
Leadership, Planning and Evaluation$454,778
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$258,634
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$250,000
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$200,000
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$115,000
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$63,767
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$49,289
P30 · FY2019 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$4,590,130
P30 · FY2018 · CA · contact PI
Developmental Funds$821,254
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$468,263
P30 · FY2018 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$250,000
P30 · FY2018 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$136,232
P30 · FY2018 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$75,711
P30 · FY2018 · CA · contact PI
UW Comprehensive CANCER CENTER SUPPORT$31,772
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$10,869
P30 · FY2018 · CA · contact PI
Developmental Funds$10,869
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$5,922
P30 · FY2018 · CA · contact PI
Developmental Funds$5,922
P30 · FY2018 · CA · contact PI
Developmental Funds$5,684
P30 · FY2018 · CA · contact PI
Developmental Funds$3,291
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$3,291
P30 · FY2018 · CA · contact PI
Leadership, Planning and Evaluation$3,241
P30 · FY2018 · CA · contact PI
UW Comprehensive Cancer Center Support$4,288,496
P30 · FY2017 · CA · contact PI
UW Comprehensive Cancer Center Support$125,000
P30 · FY2017 · CA · contact PI
UW Comprehensive Cancer Center Support$31,772
P30 · FY2017 · CA · contact PI
UW Comprehensive Cancer Center Support$4,288,496
P30 · FY2016 · CA · contact PI
UW Comprehensive Cancer Center Support$125,000
P30 · FY2016 · CA · contact PI
UW Comprehensive Cancer Center Support$4,288,496
P30 · FY2015 · CA · contact PI
UW Comprehensive Cancer Center Support$125,000
P30 · FY2015 · CA · contact PI
UW Comprehensive Cancer Center Support$37,429
P30 · FY2015 · CA · contact PI
UW Comprehensive Cancer Center Support$4,421,130
P30 · FY2014 · CA · contact PI
Developmental Funds$482,269
P30 · FY2014 · CA · contact PI
Administration$403,686
P30 · FY2014 · CA · contact PI
Cancer Informatics Shared Resource$337,322
P30 · FY2014 · CA · contact PI
Biostatistics Shared Resource$333,005
P30 · FY2014 · CA · contact PI
Human Cancer Virology Program$324,544
P30 · FY2014 · CA · contact PI
Senior Leadership$275,505
P30 · FY2014 · CA · contact PI
Clinical Research Coordinating Office$204,183
P30 · FY2014 · CA · contact PI
Data and Safety Monitoring/ NIH Policy$199,459
P30 · FY2014 · CA · contact PI
Translational Science BioCore$180,194
P30 · FY2014 · CA · contact PI
Flow Cytometry$178,041
P30 · FY2014 · CA · contact PI
Protocol Review and Monitoring System$177,043
P30 · FY2014 · CA · contact PI
Small Animal Imaging Facility$174,077
P30 · FY2014 · CA · contact PI
Experimental Pathology$163,953
P30 · FY2014 · CA · contact PI
Analytical Instrument Lab for Pharmacokinetics Pharmacodynamics Pharmacogenetics$153,374
P30 · FY2014 · CA · contact PI
UW Comprehensive Cancer Center Support$150,000
P30 · FY2014 · CA · contact PI
Transgenic and Mutant Animal Facility$149,569
P30 · FY2014 · CA · contact PI
Survey Research$148,459
P30 · FY2014 · CA · contact PI
Small Molecule Screening and Synthesis Facility$147,099
P30 · FY2014 · CA · contact PI
Pharmaceutical Research Center$136,102
P30 · FY2014 · CA · contact PI
Planning and Evaluation$129,509
P30 · FY2014 · CA · contact PI
Protocol-Specific Research Support$123,737
P30 · FY2014 · CA · contact PI
UW Comprehensive Cancer Center Support$122,401
P30 · FY2014 · CA · contact PI
UW Comprehensive Cancer Center Support$74,856
P30 · FY2014 · CA · contact PI
UW Comprehensive Cancer Center Support$4,133,528
P30 · FY2013 · CA · contact PI
UW Comprehensive Cancer Center Support$122,414
P30 · FY2013 · CA · contact PI
UW Comprehensive Cancer Center Support$37,429
P30 · FY2013 · CA · contact PI
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents$1,586,646
N01 · FY2011 · CA · contact PI
Clinical Research Central Office$322,456
P30 · FY2011 · CA · contact PI
Program Leaders$233,041
P30 · FY2011 · CA · contact PI
Enhancing Bioavailability of Resveratrol$187,979
R21 · FY2011 · CA
Protocol Specific$117,007
P30 · FY2011 · CA · contact PI
Enhancing Bioavailability of Resveratrol$308,138
R21 · FY2010 · CA
Clinical Research Central Office$297,371
P30 · FY2010 · CA · contact PI
Program Leaders$228,146
P30 · FY2010 · CA · contact PI
Protocol Specific$138,729
P30 · FY2010 · CA · contact PI
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents$1,664,000
N01 · FY2009 · CA · contact PI
Clinical Research Central Office$282,297
P30 · FY2009 · CA · contact PI
Program Leaders$216,581
P30 · FY2009 · CA · contact PI
Protocol Specific$131,689
P30 · FY2009 · CA · contact PI
Clinical Research Central Office$279,087
P30 · FY2008 · CA · contact PI
Program Leaders$214,118
P30 · FY2008 · CA · contact PI
Protocol Specific$130,196
P30 · FY2008 · CA · contact PI
Clinical Research Central Office$296,256
P30 · FY2007 · CA · contact PI
Program Leaders$227,290
P30 · FY2007 · CA · contact PI
Protocol Specific$138,206
P30 · FY2007 · CA · contact PI
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS$3,555
M01 · FY2007 · RR · contact PI
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS$21,101
M01 · FY2006 · RR · contact PI
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS --261035153$0
N01 · FY2006 · CN · contact PI
DFMO Prevention Study (2b) in Organ Transplant Subjects$257,443
R01 · FY2005 · CA
Chemoprevention of Skin Cancer - DFMO Phase III Trial$131,693
R01 · FY2005 · CA
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE III TRIAL$38,576
M01 · FY2005 · RR
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS$6,367
M01 · FY2005 · RR
Chemoprevention of Skin Cancer - DFMO Phase III Trial$439,027
R01 · FY2004 · CA
DFMO Prevention Study (2b) in Organ Transplant Subjects$250,327
R01 · FY2004 · CA
Chemoprevention of Skin Cancer: Difluoromethylornithine (DFMO) Phase III Trial$43,909
M01 · FY2004 · RR
DFMO Prevention Study (2b) in Organ Transplant Subjects$246,305
R01 · FY2003 · CA
DFMO Prevention Study (2b) in Organ Transplant Subjects$250,945
R01 · FY2002 · CA
CHEMOPREVENTION OF SKIN CANCER--DFMO PHASE 3 TRIAL$220,496
U01 · FY2002 · CA
PHASE II TRIAL OF IV L-PAM AND BSO IN RELAPSED OR REFRACTORY OVARIAN CANCER$106,600
M01 · FY2002 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA$106,600
M01 · FY2002 · RR
PHASE I EVALIUATION OF INTRAVENOUS MGI114 IN PATIENTS WITH ADVANCED CANCER$106,600
M01 · FY2002 · RR
CHEMOPREVENTION OF SKIN CANCER--DFMO PHASE 3 TRIAL$489,934
U01 · FY2001 · CA
PHASE II TRIAL OF IV L-PAM AND BSO IN RELAPSED OR REFRACTORY OVARIAN CANCER$106,600
M01 · FY2001 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA$106,600
M01 · FY2001 · RR
PHASE I EVALIUATION OF INTRAVENOUS MGI114 IN PATIENTS WITH ADVANCED CANCER$106,600
M01 · FY2001 · RR
PHASE II TRIAL OF IV L-PAM AND BSO IN RELAPSED OR REFRACTORY OVARIAN CANCER$12,855
M01 · FY2001 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA$12,855
M01 · FY2001 · RR
PHASE I EVALIUATION OF INTRAVENOUS MGI114 IN PATIENTS WITH ADVANCED CANCER$12,855
M01 · FY2001 · RR
PHASE II STUDY OF L PAM PLUS BSO IN PATIENTS W/ METASTATIC MELANOMA$12,855
M01 · FY2000 · RR
PHASE I EVALIUATION OF INTRAVENOUS MGI114 IN PATIENTS WITH ADVANCED CANCER$12,855
M01 · FY2000 · RR
PHASE II TRIAL OF IV L-PAM AND BSO IN RELAPSED OR REFRACTORY OVARIAN CANCER$0
M01 · FY2000 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL 4 TIMES /DAY$0
M01 · FY2000 · RR
PHASE I TRIAL OF PERILLYL ALCOHOL 4 TIMES /DAY$0
M01 · FY2000 · RR
PERILLYL ALCOHOL (NSC 641066) DAILY IN METASTATIC BREAST CANCER$0
M01 · FY2000 · RR
PERILLYL ALCOHOL (NSC 641066) DAILY IN METASTATIC BREAST CANCER$0
M01 · FY2000 · RR
PHASE II TRIAL OF IV L-PAM AND BSO IN RELAPSED OR REFRACTORY OVARIAN CANCER$0
M01 · FY2000 · RR